ArticleCureus2025
Histological Response and Prognostic Factors in Gastric Adenocarcinoma Treated With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) Chemotherapy: A Retrospective Single-Center Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant chemotherapy is widely used in the management of resectable gastric adenocarcinoma and is considered an important component of multimodal treatment. This study provides real-world evidence on histological response patterns following fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy, suggesting that tumor biology may play a more relevant role than regimen selection in determining pathological response.
methodsWe conducted a retrospective study including 104 patients who underwent curative surgery for gastric adenocarcinoma between January 2015 and December 2024. Patients were divided into two groups according to the neoadjuvant chemotherapy regimen: FLOT or other protocols. Tumor regression was evaluated by the Becker criteria. Clinicopathological variables were analyzed to identify predictors of histological response.
resultsOf the 104 patients, 68 received the FLOT regimen, while 36 received alternative regimens. There was no statistically significant difference in the Becker regression between the FLOT and non-FLOT groups (p = 0.08). Within the FLOT cohort, factors associated with poorer tumor regression included poor differentiation, advanced T stage, nodal metastasis, lymphatic and perineural invasion (all p<0.05). Poorer histological response correlated with higher recurrence rates and shorter disease-free survival.
conclusionsThe type of neoadjuvant chemotherapy did not significantly influence Becker regression in this cohort. Tumor biology and pathological staging remain key determinants of response. These findings reinforce the importance of individualized treatment strategies and suggest a role for biomarkers to guide therapeutic decisions in gastric cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.